Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Spy Crt MARKHAM ON L3R 5H6 |
Tel: | N/A |
Website: | https://www.edesabiotech.com |
IR: | See website |
Key People | ||
Michael J. Brooks President | Pardeep Nijhawan Chief Executive Officer, Corporate Secretary, Director | Stephen Lemieux Chief Financial Officer |
Business Overview |
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition. |
Financial Overview |
For the fiscal year ended 30 September 2024, Edesa Biotech Inc revenues was not reported. Net loss decreased 26% to $6.2M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 24% to $7M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.93 to -$1.93. |
Employees: | 16 as of Dec 13, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5.12M as of Sep 30, 2024 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2024 |
EBITDA (TTM): | -$6.83M as of Sep 30, 2024 |
Net annual income (TTM): | -$6.17M as of Sep 30, 2024 |
Free cash flow (TTM): | -$4.89M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 3,467,658 as of Dec 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |